A new multi-center, international study led by Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia shows that recombinant activated factor VII (rFVIIa) has the potential to be a significant advance in treating bleeding stroke (acute intracerebral hemorrhage or ICH). Published in the New England Journal of Medicine
(Feb. 24 issue), the study found a reduction in hematoma growth (bleeding in the brain), decreased mortality, and improvement in neurological and clinical outcomes in patients treated with rFVIIa compared to placebo.
ICH is the deadliest and most disabling type of stroke more than one out of three ICH patients die within one month of onset and only 20% regain functional independence. Physicians have long been frustrated by a lack of effective therapies to improve survival outcomes or recovery current options are only supportive. RFVIIa is currently entering phase III trials as an investigational treatment for ICH. If approved by the U.S. Food and Drug Administration, it will become only the second emergency treatment for stroke in more than three decades the first was TPA, approved by the FDA in 1996.
"Current medical and surgical options for ICH are not effective. Thirty-five to 50 percent of patients die within one month and if they survive, they live with serious neurological deficits. Current data suggest a possible change in our paradigm for the treatment of ICH," said Stephan A. Mayer, M.D., principal investigator of the study. Dr. Mayer is an associate professor of neurology and neurosurgery at Columbia University College of Physicians and Surgeons, and director of the Neurological Intensive Care Unit at NewYork-Presbyterian Hospital/Columbia.
"I approached this study with modest expectations, expecting to see some trends toward improved outcomes," noted Dr. Mayer. "I was stunned to find that by preventing just 5 ml of additional blood about one teaspoon of bleeding inPage: 1 2 3 4 Related medicine news :1
Contact: Elizabeth Streich
Columbia University Medical Center
. Columbia researchers receive $3 million to combat genetic killer of infants & toddlers2
. Columbia study shows widely used artery clearing device does not help patients during heart attack3
. First US kidney cancer vaccine trial underway at Columbia4
. RelayHealth selected by Columbia University to link doctors and patients online5
. Harlem Hospital Center, Columbia affiliate, recognized for efforts to fight glaucoma6
. Research by scientists affiliated with the Earth Institute at Columbia University7
. Columbia Univ. Medical Center wins highly competitive stroke grant from NIH8
. Brain Science Institute at Columbia University established by Kavli Foundation gift9
. Earth Institute at Columbia University hosts State of the Planet 200410
. The Gerontological Society of America confers 2003 Lawton Award to Columbia Universitys Gurland11
. Russell Berrie Foundation gift to Columbia University propels diabetes treatment into new era